News on Urology continually updated from thousands of sources around the net.
9 hrs ago | WebMD
Talk to health experts and other people like you in WebMD's Communities. It's a safe forum where you can create or participate in support groups and discussions about health topics that interest you.
Trending on the Topix Network
13 hrs ago | Newham Recorder
Community leaders and medical experts have played a major role in the launch of a national report that aims to tackle prostate cancer in black men.
16 hrs ago | Business Wire
As a result, Dr. John Pumphrey and Dr. Michael Walter will join USMD's physician group.
For your information: MNT accounts were not affected by the recent Heartbleed bug, as we were not running a vulnerable version of OpenSSL.
Daily supplements containing extracts from a blend of green and black tea varieties may improve lower urinary tract symptoms and quality of life in men in as little as six weeks, says a new study.
Men who receive adjuvant radiation therapy following radical prostatectomy face a significantly increased risk of urinary incontinence in the following years, study findings indicate.
Urologists at Rush University Medical Center are the first in Chicago to offer a powerful new tool for visualizing and monitoring the prostate in men who have high prostate-specific antigen levels and in detecting prostate cancer more accurately.
Prostate cancer is the most common cancer in men, and in 2010, it was responsible for over 28,000 deaths in the US.
Astellas Pharma Europe Ltd., the European subsidiary of Tokyo-based Astellas Pharma Inc. , announced the results of two separate studies at the annual European Association of Urology congress.
The Astellas European Foundation is pleased to announce the recipient of the 2014 Functional Urology and Uro-Gynaecology Grant as Dr to quantify marker levels to identify the potential relationship between Overactive Bladder Syndrome and Bladder Pain Syndrome / Interstitial Cystitis.
April 11, 2014 - Dendreon Corporation today announced the presentation of preliminary data from a long-term analysis of the Phase II STAND study demonstrating that tumor-specific T-cell responses appear to be enhanced and sustained when PROVENGE is given after androgen deprivation therapy in patients with biochemically-recurrent prostate cancer at ... (more)
The first poster presentation demonstrates the clinical validation of the DecipherA prostate cancer classifier for predicting treatment failure in men treated with post-surgery radiation therapy.
Urologix , Inc. , the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, today announced a strategic restructuring of its organizational infrastructure and reported preliminary financial results for its fiscal year 2014 third quarter ended March 31, 2014.